Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis

Sarcoidosis is characterised by non-caseating granulomas that secrete pro-inflammatory cytokines, including interleukin (IL)-12, IL-23, and tumour necrosis factor (TNF)-α. Ustekinumab and golimumab are monoclonal antibodies that specifically inhibit IL-12/IL-23 and TNF-α, respectively. Patients with...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The European respiratory journal 2014-11, Vol.44 (5), p.1296-1307
Hauptverfasser:	JUDSON, Marc A, BAUGHMARI, Robert P, WIJSENBEEK, Marlies S, ALBERA, Carlo, HUIZAR, Isham, AGARWAL, Prasheen, BRODMERKEL, Carrie, WATT, Rosemary, BARNATHAN, Elliot S, COSTABEL, Ulrich, DRENT, Marjolein, GIBSON, Kevin F, RAGHU, Ganesh, SHIGEMITSU, Hidenobu, BARNEY, Joseph B, CULVER, Daniel A, HAMZEH, Nabeel Y
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized - therapeutic use Antirheumatic Agents - therapeutic use Biological and medical sciences Chronic Disease Double-Blind Method Female Humans Interleukin-12 - antagonists & inhibitors Interleukin-23 - antagonists & inhibitors Male Medical sciences Middle Aged Pneumology Sarcoidosis - drug therapy Sarcoidosis - physiopathology Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis Tumor Necrosis Factor-alpha - antagonists & inhibitors Ustekinumab
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!